Chiesi Farmaceutici S.p.a.

This study is testing an enzyme replacement therapy called PRX-102 in children and adolescents aged 2 to 17 who have Fabry disease, a rare genetic disorder. The main goals are to find the safest and most effective dose for young patients and to see how well the treatment works at…

This study is testing a new inhaled drug called CHF6333 to see if it is safe for people with bronchiectasis, a condition that causes permanent lung damage and frequent infections. First, single doses will be given to healthy volunteers and people with the disease. Then, repeated …

This study aims to see if a new asthma inhaler, which uses a more climate-friendly gas, works just as well as current inhalers. About 780 adults with mild to moderate asthma will try both inhalers to compare their safety and effectiveness. The main goal is to ensure the new, envi…

This study is testing whether Oleogel-S10 gel helps close wounds in people with two types of epidermolysis bullosa (EB), a rare genetic condition that causes fragile, blistering skin. Japanese children and adults with confirmed EB will apply the gel to their wounds for 45 days wh…

This study is observing 100 adults with Fabry disease who are already taking or planning to take the medication Elfabrio® as part of their regular care. Researchers will collect information from medical records and ongoing check-ups to see how well the drug works and how safe it …

This study is testing a new drug called pegunigalsidase alfa (PRX-102) for Japanese adults and teenagers with Fabry disease, a rare genetic disorder. The main goal is to see if the drug is safe and if it can help prevent or reduce the health problems caused by the disease. Partic…

This is an early safety study testing an experimental nasal spray called CHF6467 in 68 healthy adults. Researchers want to see if the spray is safe and how the body processes it, including whether it reaches the fluid around the brain and spinal cord. The study will test single d…